Related Experiment Video
Updated: May 6, 2026

The Monoiodoacetate Model of Osteoarthritis Pain in the Mouse
Published on: May 16, 2016
Chemokine expression in peripheral tissues from the monosodium iodoacetate model of chronic joint pain
John M Dawes1, Hannes Kiesewetter, James R Perkins
1Nuffield Department of Clinical Neurosciences, West Wing, Level 6, John Radcliffe Hospital, Oxford OX3 9DU, UK. john.dawes@ndcn.ox.ac.uk.
Background:
Chronic pain arising from degenerative diseases of the joint such as osteoarthritis (OA) has a strong peripheral component which is likely to be mediator driven. Current treatments which reduce the production of such mediators i.e. non-steroidal anti-inflammatory drugs (NSAIDs), can help to lessen pain in OA patients. However, this is not always the case and complete pain relief is rarely achieved, suggesting that additional unidentified mediators play a role. Here we have investigated the notion that chemokines might act as such pain mediators in OA.
Results:
Using the monosodium iodoacetate (MIA) model of chronic joint pain the expression of over 90 different inflammatory mediators, mainly cytokines and chemokines, were measured in tissues taken from the femorotibial joint (cartilage, subchondral bone, fat pad) using custom-made quantitative real-time polymerase chain reaction (qPCR) array cards. At both the day 3 and 14 time points, numerous inflammatory mediators were significantly up-regulated in these tissues, although it was clear that the largest transcriptional dysregulation occurred in the cartilage. Using individual qPCR to measure immune cell markers, a significant infiltration of macrophages was measured in the cartilage and fat pad at day 3. Neutrophil infiltration was also measured in the fat pad at the same time point, but no infiltration was observed at day 14. Combination of mRNA expression data from different time points and tissues identified the chemokines, CCL2, 7 and 9 as being consistently up-regulated. The overall increase in CCL2 expression was also measured at the protein level.
Conclusion:
Chemokines in general and CCL2, 7 and 9 in particular, represent promising targets for further studies into the identification of new pain mediators in chronic joint pain.
Insights
Chemokines, such as CCL2, 7, and 9, are identified as potential pain mediators in osteoarthritis (OA). These findings suggest new therapeutic targets for chronic joint pain management.
Area of Science:
- Biomedical Science
- Immunology
- Pain Research
Background:
- Chronic joint pain, often linked to osteoarthritis (OA), involves peripheral mediators.
- Current non-steroidal anti-inflammatory drugs (NSAIDs) offer incomplete pain relief, indicating unidentified pain mediators.
- This study investigates the role of chemokines as potential pain mediators in OA.
Purpose of the Study:
- To explore the potential role of chemokines as pain mediators in osteoarthritis.
- To identify specific inflammatory mediators, particularly chemokines, involved in chronic joint pain.
Main Methods:
- Utilized the monosodium iodoacetate (MIA) model to induce chronic joint pain in a preclinical setting.
- Measured the expression of over 90 inflammatory mediators using custom quantitative real-time polymerase chain reaction (qPCR) arrays in joint tissues.
- Assessed immune cell infiltration (macrophages, neutrophils) and chemokine expression at both mRNA and protein levels at different time points.
Main Results:
- Significant upregulation of numerous inflammatory mediators, especially chemokines, was observed in joint tissues (cartilage, subchondral bone, fat pad) at days 3 and 14 post-MIA injection.
- Macrophage infiltration was prominent in cartilage and fat pads by day 3, with neutrophil infiltration in the fat pad.
- Chemokines CCL2, CCL7, and CCL9 were consistently upregulated across tissues and time points, with increased CCL2 protein levels.
Conclusions:
- Chemokines, specifically CCL2, CCL7, and CCL9, are implicated as significant pain mediators in chronic joint pain models.
- These chemokines represent promising therapeutic targets for developing novel treatments for osteoarthritis-related pain.
Related Concept Videos
Chronic Inflammation: Introduction
Acute Inflammation II: Local and Systemic Effects
Acute Inflammation I: Inflammatory Response

